Preclinical antileukemia activity of JNJ-26481585, a potent second-generation histone deacetylase inhibitor.
Preclinical antileukemia activity of JNJ-26481585, a potent second-generation histone deacetylase inhibitor. Leuk Res. 2010 Feb; 34(2):221-8.